

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.,
Petitioner,
v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 10,888,601

Inter Partes Review No. IPR2023-00739

PATENT OWNER'S PRELIMINARY RESPONSE

	Page
I. INTRODUCTION	1
II. BACKGROUND	4
A. EYLEA®	4
B. The '601 Patent	8
C. District Court Litigation	9
III. LEVEL OF ORDINARY SKILL IN THE ART	11
IV. CLAIM CONSTRUCTION	11
V. PETITIONER HAS NO REASONABLE LIKELIHOOD OF SUCCESS BECAUSE THE RECITED DOSING REGIMEN IS NOT DISCLOSED OR SUGGESTED BY THE PRIOR ART	11
A. Petitioner Fails to Show That the 2009 Press Release or Shams Would Lead a POSA to the Recited Dosing Regimen (Ground 2)	11
1. The References Neither Disclose the Recited Dosing Regimen nor Provide Any Reason for a POSA to Adopt That Regimen	12
2. The Relied-Upn Prior Art Teaches Away from the Recited Dosing Regimen	17
3. The “Routine Adjustments” Methodology Petitioner Advocates Does Not Render the Challenged Claims Obvious	22
B. Petitioner Fails to Show That Elman 2010 in Combination with the 2009 Press Release Would Lead a POSA to the Recited Dosing Regimen (Grounds 3 and 6)	25
1. Petitioner’s References Do Not Disclose, and Instead Teach Away from, the Recited Dosing Regimen	25
2. Petitioner Fails to Show a Motivation to Combine	34
VI. THE <i>FINTIV</i> FACTORS WEIGH AGAINST INSTITUTION	37
A. Legal Standard for <i>Fintiv</i> Discretionary Denial	39

TABLE OF CONTENTS
(continued)

	Page
1. <i>Fintiv</i> Factors One, Two, Three, Four, and Six Favor Denial	40
2. <i>Fintiv</i> Factor Five Is Neutral.....	44
VII. CONCLUSION.....	45

TABLE OF AUTHORITIES**Page(s)****Cases**

<i>Apotex Inc. v. Novartis AG</i> , IPR2017-00854, 2018 WL 3414289 (P.T.A.B. July 11, 2018).....	21
<i>Apple Inc. v. Fintiv, Inc.</i> , IPR2020-00019, 2020 WL 2126495 (P.T.A.B. Mar. 20, 2020).....	<i>passim</i>
<i>In re Bell</i> , 991 F.2d 781 (Fed. Cir. 1993)	15
<i>Biomarin Pharm. Inc. v. Genzyme Therapeutic Prods. Ltd. P'ship</i> , IPR2013-00534, Paper 81 (P.T.A.B. Feb. 23, 2015).....	23
<i>Commscope Techs. LLC v. Dali Wireless, Inc.</i> , No. IPR2022-01293, 2023 WL 2604001 (P.T.A.B. Mar. 9, 2023).....	41
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Pat.</i> <i>Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012)	16, 21
<i>Fitbit, Inc. v. Philips N. Am. LLC</i> , IPR2020-00828, 2020 WL 6470312 (P.T.A.B. Nov. 3, 2020).....	45
<i>Google LLC v. Personalized Media Commc'ns, LLC</i> , IPR2020-00724, 2020 WL 6530785 (P.T.A.B. Nov. 5, 2020).....	45
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	15, 16
<i>In re Kubin</i> , 561 F.3d 1351 (Fed. Cir. 2009)	16
<i>Leo Pharm. Prods., Ltd. v. Rea</i> , 726 F.3d 1346 (Fed. Cir. 2013)	16, 36
<i>Life Spine, Inc. v. Globus Medical, Inc.</i> , IPR2022-01603, Paper 8 (P.T.A.B. June 12, 2023)	14

IPR2023-00739

<i>NHK Spring Co. v. Intri-Plex Techs., Inc.</i> , IPR2018-00752, Paper 8 (P.T.A.B. Sept. 12, 2018).....	38, 41
<i>In re NTP, Inc.</i> , 654 F.3d 1279 (Fed. Cir. 2011)	15
<i>Ortho-McNeil Pharm., Inc. v. Mylan Lab'ys, Inc.</i> , 520 F.3d 1358 (Fed. Cir. 2008)	36
<i>Portney v. CIBA Vision Corp.</i> , 401 F. App'x 526 (Fed. Cir. 2010)	10
<i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , 1:22-cv-00061-TSK-JPM (N.D. W. Va.)	37
<i>Samsung Elecs. Co. v. Clear Imaging Rsch., LLC</i> , IPR2020-01399, Paper 13 (P.T.A.B. Feb. 3, 2021).....	42
<i>Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd.</i> , 492 F.3d 1350 (Fed. Cir. 2007)	16
<i>TWI Pharms, Inc. v. Merck Serono SA</i> , IPR2023-00050, Paper 8 (P.T.A.B. Mar. 28, 2023)	17
<i>Unigene Lab'ys, Inc. v. Apotex, Inc.</i> , 655 F.3d 1352 (Fed. Cir. 2011)	36
<i>Volvo Penta of the Ams., LLC v. Brunswick Corp.</i> , IPR2022-01366, Paper 15 (P.T.A.B. May 2, 2023)	41

Statutes

35 U.S.C. § 314(a)	37, 38
42 U.S.C. § 262	9

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.